title: Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks.
abstract: In the PREVENIR-5 study, artificial neural networks (NN) were applied to a large sample of patients with recent first acute coronary syndrome (ACS) to identify determinants of persistence of evidence-based cardiovascular medications (EBCM: antithrombotic + beta-blocker + statin + angiotensin converting enzyme inhibitor-ACEI and/or angiotensin-II receptor blocker-ARB). From October 2006 to April 2007, 1,811 general practitioners recruited 4,850 patients with a mean time of ACS occurrence of 24 months. Patient profile for EBCM persistence was determined using automatic rule generation from NN. The prediction accuracy of NN was compared with that of logistic regression (LR) using Area Under Receiver-Operating Characteristics-AUROC. At hospital discharge, EBCM was prescribed to 2,132 patients (44%). EBCM persistence rate, 24 months after ACS, was 86.7%. EBCM persistence profile combined overweight, hypercholesterolemia, no coronary artery bypass grafting and low educational level (Positive Predictive Value = 0.958). AUROC curves showed better predictive accuracy for NN compared to LR models.
authors: THEMIS-ICTA Group, Bioparc-60 Avenue Rockefeller, Lyon 69008, France. valerie.bourdes@themis-rd.fr
authors: Valérie
authors: V
authors: Bourdès
authors: Jean
authors: J
authors: Ferrières
authors: Jacques
authors: J
authors: Amar
authors: Elisabeth
authors: E
authors: Amelineau
authors: Stéphane
authors: S
authors: Bonnevay
authors: Maryse
authors: M
authors: Berlion
authors: Nicolas
authors: N
authors: Danchin
references: Anaesthesia. 2006 Apr;61(4):335-8
references: 16548951
references: Int J Epidemiol. 2002 Dec;31(6):1253-62; discussion 1262-64
references: 12540731
references: J Manag Care Pharm. 2008 Apr;14(3):271-80
references: 18439049
references: Am Heart J. 2007 Dec;154(6):1108-15
references: 18035083
references: Pharmacoeconomics. 1999 Aug;16(2):175-81
references: 10539398
references: IEEE Trans Neural Netw. 2006 Mar;17(2):374-84
references: 16566465
references: Ann Med. 2004;36(8):630-40
references: 15768835
references: Ann Cardiol Angeiol (Paris). 2005 Dec;54 Suppl 1:S30-6
references: 16411649
references: Psychol Rev. 1958 Nov;65(6):386-408
references: 13602029
references: BMJ. 2003 Jun 7;326(7401):1259-61
references: 12791748
references: Am Heart J. 2006 Jan;151(1):185-91
references: 16368315
references: Heart. 2005 Mar;91(3):290-8
references: 15710703
references: Int J Cardiol. 2005 Jun 8;101(3):481-7
references: 15907418
references: J Pharm Biomed Anal. 2000 Jun;22(5):717-27
references: 10815714
references: Am J Health Syst Pharm. 2000 Jan 15;57(2):139-45
references: 10688242
references: Lancet. 1995 Oct 21;346(8982):1075-9
references: 7564791
references: Eur Heart J. 2002 Aug;23(15):1190-201
references: 12127921
references: J Am Geriatr Soc. 2009 Nov;57(11):1990-6
references: 19754499
references: J Clin Epidemiol. 1996 Nov;49(11):1225-31
references: 8892489
references: Eur Heart J. 2007 Jul;28(13):1598-660
references: 17569677
references: BMJ. 1995 Jul 29;311(7000):293-5
references: 7633238
references: Eur Heart J. 2003 Jan;24(1):28-66
references: 12559937
references: Eur Heart J. 2005 Apr;26(8):804-47
references: 15769784
references: Eur Heart J. 2001 Apr;22(7):554-72
references: 11259143
references: JAMA. 2002 Jul 24-31;288(4):462-7
references: 12132976
references: Am J Med. 2004 Jul 15;117(2):73-81
references: 15234641
references: Arch Cardiovasc Dis. 2008 May;101(5):301-6
references: 18656088
references: Int J Clin Pharmacol Ther. 1998 Apr;36(4):195-201
references: 9587045
references: Am J Cardiovasc Drugs. 2007;7(2):95-116
references: 17503881
references: Am Heart J. 2005 Dec;150(6):1147-53
references: 16338251
references: Eur Heart J. 2000 Sep;21(18):1502-13
references: 10973764
references: Am J Cardiol. 1997 Mar 1;79(5):581-6
references: 9068512